Abstract:BACKGROUND:Breast cancer stem cells (BCSCs) play essential roles in tumor metastasis and contribute to remarkably negative clinical outcomes. Recently, aldehyde dehydrogenase (ALDH) and CD44 positivity (ALDH(+)/CD44(+)) was identified as a marker of BCSCs in vitro/in vivo studies. The aim of this study was to evaluate the prevalence of ALDH(+)/CD44(+) cells in breast cancer and the association of these two markers with clinicopathological features and clinical outcomes. MATERIALS AND METHODS:We investigated the prevalence of ALDH1A3(+)/CD44(+) cells in a cohort of 144 formalin-fixed, paraffin-embedded (FFPE) breast cancer tissues. The tissues were stained for ALDH1A3 and CD44 by single and dual immunohistochemistry (dIHC). The associations among the prevalence of ALDH1A3(+)/CD44(+) cells, the clinicopathological features and the clinical outcomes of the patients were also analyzed. RESULTS:ALDH1A3(+)/CD44(+) cells were present in 39 patients (27.1%). By the Mann-Whitney U test, the Pearson Chi-square test or Fisher's exact test, it was demonstrated that the prevalence of ALDH1A3(+)/CD44(+) cells was closely correlated with larger tumor size (p=0.001), nodal metastasis status (p=0.043), more advanced clinical stage (p=0.021) and distant metastasis after initial surgery (p=0.001). In a univariate survival analysis, the presence of ALDH1A3(+)/CD44(+) tumor cells had a significant negative association with both disease-free survival (DFS) and overall survival (OS) (pDFS<0.001; pOS<0.001). The negative clinical outcomes in ALDH1A3(+)/CD44(+) tumors were further confirmed by a multivariate analysis using Cox proportional hazard models (pDFS<0.001, HR=3.155; pOS=0.001, HR=3.193). This was also true with respect to the clinical treatment regimens of chemotherapy (pDFS<0.001; pOS=0.001), radiotherapy (pDFS=0.004; pOS=0.004), and endocrine therapy (pDFS<0.001; pOS<0.001). CONCLUSION:In summary, our results indicate that the prevalence of ALDH1A3(+)/CD44(+) tumor cells in breast cancer is significantly associated with worse prognostic factors and favors a poor prognosis.

Aldehyde Dehydrogenase 1 Expression is Correlated with Poor Prognosis in Breast Cancer

The Expression of Aldehyde Dehydrogenase 1 in Invasive Primary Breast Tumors and Axillary Lymph Node Metastases is Associated with Poor Clinical Prognosis.

Distinct prognostic values of ALDH1 isoenzymes in breast cancer

The Expression of Aldehyde Dehydrogenase Family in Breast Cancer.

Expression of ALDH 1 in atypical ductal hyperplasia , carcinoma , usual ductal hyperplasia and normal breast duct

Aldehyde Dehydrogenase 1 Expression Correlates with Clinicopathologic Features of Patients with Breast Cancer: A Meta-Analysis

Aldehyde dehydrogenase 1 (ALDH1) positivity correlates with poor prognosis in cervical cancer.

Clinical significance of ALDH1 expression in breast cancer:a Meta analysis

Aldehyde Dehydrogenase 1 (ALDH1) Immunostaining in Axillary Lymph Node Metastases is an Independent Prognostic Factor in ALDH1-positive Breast Cancer

Clinicopathological Significance of ALDH1A1 in Lung, Colorectal, and Breast Cancers: a Meta-Analysis.

Abstract P2-06-12: The expression of aldehyde dehydrogenase1 in cytoplasm or stroma of breast cancer is associated with clinical prognosis

Expression Of Aldh1 And Tgf Beta 2 In Benign And Malignant Breast Tumors And Their Prognostic Implications

ALDH(+)/CD44(+) cells in breast cancer are associated with worse prognosis and poor clinical outcome.

Aldehyde Dehydrogenase 3A1 is Robustly Upregulated in Gastric Cancer Stem-Like Cells and Associated with Tumorigenesis.

Aldehyde Dehydrogenases and Cancer Stem Cells.

Prognostic and immunological role of acetaldehyde dehydrogenase 1B1 in human tumors: A pan-cancer analysis

Increased Expression of ALDH1A1 Protein is Associated with Poor Prognosis in Clear Cell Renal Cell Carcinoma

Aldehyde dehydrogenase 1 expression in cancer cells could have prognostic value for patients with non-small cell lung cancer who are treated with neoadjuvant therapy: identification of prognostic microenvironmental factors after chemoradiation

Decreased expression of ALDH1L1 is associated with a poor prognosis in hepatocellular carcinoma

ALDH1 is a Marker of Normal and Malignant Human Mammary Stem Cells and a Predictor of Poor Clinical Outcome.

Prognostic Value of Cancer Stem Cell Marker Aldehyde Dehydrogenase in Ovarian Cancer: a Meta-Analysis.